Proceedings Inflammatory Bowel Disease Workshop
Maintenance therapy in IBD
Dr. William J. Tremaine,
Corresponding Author
Dr. William J. Tremaine
Inflammatory Bowel Disease Clinic, Mayo Clinic, Rochester, Minnesota, U.S.A.
Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, U.S.A.Search for more papers by this authorDr. William J. Tremaine,
Corresponding Author
Dr. William J. Tremaine
Inflammatory Bowel Disease Clinic, Mayo Clinic, Rochester, Minnesota, U.S.A.
Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, U.S.A.Search for more papers by this authorFirst published: 14 December 2006
References
- 1 Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo controlled, dose-ranging study. Gastroenterology 1996; 110: 45–51.
- 2 Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995; 109: 1001–3.
- 3 Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332: 988–92.
- 4 Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540–9.
- 5 Ewe K, Herfarth C, Makhow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989; 42: 224–32.
- 6 Steinhart HA, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 216–24.
- 7 Hanauer SB, and the Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204–11.
- 8 Miner PB Jr, Hanauer SB, Robinson MR, et al. Safety and efficacy of controlled release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 1995; 40: 296–304.
- 9 Travis SP, Tysk C, de Siiva HJ, Sandberg-Gertzen H, Jewell DP, Jarnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6.
- 10 Green JR, Swan CH, Rowlinson A, Gibson JA, Brown P, Kerr GD, Swarbrick ET, Thornton P. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992; 6: 647–52.
- 11 Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M, and the Italian IBD Study Group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363–8.
- 12 Bresci G, Petrucci A, Banti S. 5-Aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study. Int J Clin Pharmacol Res 1991; 11: 200–2.
- 13 Caprilli R, Anreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid: Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8: 35–43.
- 14 Brignola C, Cottone M, Pera A, et al. Mesalamine in the Prevention of Endoscopic Recurrence after intestinal resection for Crohn's Disease. Gastroenterology 1995; 108: 345–9.
- 15 Gendre JP, Mary JY, Glorent C, et al. Oral mesalamine (Pentasa as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Group d'Etudes Tharapeutiques des Affections Inflammatoires Digestives (GETAID).) Gastroenterology 1993; 104: 435–9.
- 16 Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohns disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692–8.
- 17 Biddle WL, Greenberger NJ, Swan JT, et al. 5-aminosalicylic enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988; 94: 1075–9.
- 18 d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997; 92: 1143–7.
- 19 D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, Boscaino A, Mazzacca G. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85: 1079–82.
- 20 Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305 (6844): 20–2.
- 21 Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498–9.
- 22 O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2 (8097): 955–7.
- 23 Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990; 99: 1347–51.
- 24 Korelitz B, Hanauer Rutgeerts P, et al. Post-operative prophylazis with 6-MP, 5-ASA or placebo in Crohn's disease: a 2 year multi-center trial [Abstr.]. Gastroenterology 1998; 114: A1011.
- 25 Kozarek RA, Patterson DJ, Gelfand, et al. Long-term use or Methotrexate in inflammatory bowel disease: severe disease 3, drug therapy 2. Seventh Inning Stretch. Gastroenterology 1992; 702: A648.
- 26 Feagan BG, Rochon J, Fedorak RN, et al, for The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292–7.
- 27 Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383–7.
- 28 Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617–21.
- 29 Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomized controlled trial. Gut 1992; 33: 922–8.
- 30 Greenfield SM, Green AT, Teare JP, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993; 7: 159–66.
- 31 Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's Disease. N Eng J Med 1916; 334: 1557–60.
- 32 Jones VA, Dickinson RJ, Workman E, et al. Crohn's disease: maintenance of remission by diet. Lancet 1985; 2 (8448): 177–80.
- 33 Pearson M, Teahon K, Levi AJ, et al. Food intolerance and Crohn's disease. Gut 1993; 34: 783–7.
- 34 Rutgeerts P, D'Haens G, van Deventer SJH, et al. Retreatment with anti-TNF-α chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [Abstract]. Gastroenterology 1997; 112: A1078.
